Cingulate Inc. — Third Quarter 2026 Earnings Summary

Cingulate Inc. reported a net loss of $7.7 million for the third quarter of 2026, driven primarily by increased selling, general, and administrative expenses related to commercial readiness. The company has substantially completed manufacturing work to address FDA requests for its CTx-1301 ADHD drug application and expects to resubmit the new drug application between December 2026 and January 2027. As of September 30, 2026, Cingulate held approximately $23.2 million in cash and cash equivalents, which is projected to fund operations through mid-2027.